ANCA-associated Vasculitis research hub

Avacostar - (PASS)

This study looks at people with a serious condition called ANCA-associated vasculitis (AAV). It compares a new medicine, avacopan, with standard treatments to see how people get on and if there are any specific health events. It's not a trial where you get a new treatment, but observes real-world care.

Subclinical Cytomegalovirus Reactivation in Acute ANCA-associated Vasculitis

ETA and AT1 Antagonism in ANCA-vasculitis (SPARVASC)

This study looks at a new drug, sparsentan, for people with ANCA-associated vasculitis. It aims to see if blocking certain chemicals can help improve blood vessel health, which is important for preventing heart attacks and strokes in these patients.